LexisNexis® Legal Newsroom
2 Drug Makers To Pay $214.5 Million For Off-Label Marketing Of Zonegran

BOSTON - (Mealey's) Drug maker Elan Corp. PLC on Dec. 15 pleaded guilty to misdemeanor branding for the off-label marketing of the epilepsy drug Zonegran and will pay more than $203.5 million in criminal and civil penalties ( United States of America v. Elan Pharmaceuticals, Inc. , No. 10-10431,...

$4 Million Awarded In 1st Pa. Trial Alleging Birth Defect From Topamax Epilepsy Drug

PHILADELPHIA — (Mealey’s) A Pennsylvania jury on Oct. 30 found that Janssen Pharmaceuticals Inc. failed to warn about the risk of birth defects from its Topamax epilepsy drug and awarded the injured minor $4 million in damages (April Czimmer, et al. v. Ortho-McNeil-Janssen Pharmaceutica,...

Pfizer To Pay $325M To Settle Neurontin 3rd-Party Payer, Antitrust Class Action

BOSTON — (Mealey’s) Pfizer Inc. has agreed to a $325 million class settlement of claims by third-party payers that allege that the off-label promotion of the epilepsy drug Neurontin violated the Racketeer Influenced and Corrupt Organizations Act and that the drug maker’s efforts to...